Jean-Charles Soria

Clinical Cancer Research Deputy Editor

Jean-Charles Soria is a newly appointed Deputy Editor of Clinical Cancer Research and is currently a Senior Vice President and Head of the Oncology Innovative Medicines unit (iMED) at MedImmune, where he has overall responsibility for the global oncology portfolio with oversight of research, translational sciences, and clinical development in oncology. His work focuses on potential therapeutic treatments for cancer, especially in precision medicine and immuno-oncology. He has contributed to first-in-man trials of atezolizumab and pembrolizumab in lung cancer.

Dr. Soria has been a member of the AACR since 1998 and has regularly presented work at AACR Annual meetings since 1999. In 2001, Dr. Soria won the AACR-AFLAC Scholar in Training Award, which provides grants to promising young investigators.

He was a scientific committee co-chairperson of the 2014, 2015, and 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposia and the 2015 AACR-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics. In 2016, he served as a co-chairperson for the AACR Annual Meeting Scientific Program Committee. In 2018, he became a Scientific Editor for Cancer Discovery.

Prior to his position at MedImmune, Dr. Soria was Head of the Drug Development Department (DITEP) at Gustave Roussy in Villejuif, France from 2013-2017. He was a Full Professor of Medicine and Medical Oncology at Paris-Sud Université XI from 2006-2017 and served as an Adjunct Professor of Medicine at the MD Anderson Cancer Center from 2013-2017. In 2018, the European Society for Medical Oncology awarded Dr. Soria the Targeted Anticancer Therapies award.

A selection of Dr. Soria’s recent articles from the AACR family of journals is provided below:

• A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics.
  Claret L, Jin JY, Ferté C, Winter H, Girish S, et al. Clinical Cancer Research July 2018
• Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
  Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, et al. Clinical Cancer Research November 2017.
• Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
  Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, et al. Clinical Cancer Research October 2017.
• A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
  Paik PK, Shen R, Berger MF, Ferry D, Soria JC, et al. Clinical Cancer Research September 2017.
• AACR Project GENIE: Powering Precision Medicine through an International Consortium.
  AACR Project GENIE Consortium. Cancer Discovery August 2017.
• Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
  Pailler E, Oulhen M, Borget I, Remon J, Ross K, et al. Cancer Research May 2017.
• High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
  Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, et al. Cancer Discovery June 2017.
• JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.
  Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC. Cancer Discovery February 2017.